Injectable alcoholism drug developed

Jun 13, 2006

A U.S. biotech firm has reportedly developed a monthly injectable alcoholism treatment as a substitute for a daily pill.

The drug -- being marketed by Cephalon Inc., in Frazer, Pa. -- was developed by Alkermes Inc. of Cambridge, Mass., as an extended-release injection form of naltrexone.

The new drug, Vivitrol, works by blocking neurotransmitters believed to be associated with alcohol dependence, diminishing the craving for alcohol, the Philadelphia Inquirer reported Tuesday.

Vivitrol has been approved by the U.S. Food and Drug Administration for use by adults able to abstain from drinking alcohol in an outpatient setting, and who are not actively drinking when they begin treatment.

The monthly intramuscular shot will cost $695, with Alkermes and Cephalon sharing profits from Vivitrol sales, as well as developing future commercial uses, possibly to treat other addictions.

Researchers told the Inquirer Vivitrol will be administered only by healthcare personnel in offices, hospitals, and clinics, and the treatment will include counseling.

Copyright 2006 by United Press International

Explore further: Researchers discover low-grade nonwoven cotton picks up 50 times own weight of oil

add to favorites email to friend print save as pdf

Related Stories

Longer-lasting options to treat drug addiction

Oct 18, 2010

(AP) -- New treatments for addiction to heroin or narcotic painkillers promise longer-lasting relief that may remove some day-to-day uncertainty of care: A once-a-month shot is now approved and a six-month implant is in ...

Recommended for you

West Africa seals off Ebola outbreak epicentre

6 hours ago

West Africa's Ebola-hit nations announced a cross-border isolation zone on Friday, sealing off the epicentre of the world's worst-ever outbreak as health chiefs warned the epidemic was spiralling out of control.

New research characterizes in-flight pediatric deaths

6 hours ago

In a first-of-its-kind study, researchers at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) found that lap infants may be at greater risk for death on a commercial airline flight. The study analyzed ...

Pepper and halt: Spicy chemical may inhibit gut tumors

7 hours ago

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining ...

Clues to curbing obesity found in neuronal 'sweet spot'

7 hours ago

Preventing weight gain, obesity, and ultimately diabetes could be as simple as keeping a nuclear receptor from being activated in a small part of the brain, according to a new study by Yale School of Medicine ...

User comments : 0